The Niche Episode 033 – Merck 3x, Parexel, NeoGenomics, 23andMe, Revolution Medicine, and Sana

Two Mercks – three stories, Paraxel gets genomes, Genomes get Money, and 2021 is the year of the upsized public offering.


Story References 

Music by Luke Goodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.


Registered Users

Please login or register to continue.